Fig. 1 · Structure

Documents & Downloads

Guaifenesin (Guaiphenesin)

Cat. No. A10443 CAS 93-14-1
Guaifenesin(Guaiphenesin) is thought to act as an expectorant.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Guaifenesin reduced MUC5AC secretion and cellular content in IL-13-stimulated primary human airway epithelial cultures. This supports a direct epithelial effect in this model; the experiment does not identify a molecular target or establish clinical mucus clearance. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Guaifenesin (Guaiphenesin) Research Summary

This section summarizes 2 in vitro studies of Guaifenesin (Guaiphenesin) from 1 published reference.

Guaifenesin (Guaiphenesin) In Vitro Studies

In IL-13-stimulated airway cultures, guaifenesin increased mucus transport at later time points and reduced secretion elasticity and viscosity at 24 hr. No significant transport effect was detected at 3 hr. Responses varied with concentration and particle class, and all cultures came from one donor. [1]

MUC5AC content and secretion in IL-13-stimulated airway cultures

Cell-based study · Primary human tracheal-bronchial epithelial cultures (MatTek EpiAirway), differentiated at air–liquid interface; a single donor. [1]

Basolateral guaifenesin reduced MUC5AC secretion and cellular content. WST-1 comparisons found no significant viability change versus IL-13 alone. Quadruplicate cultures per condition/time are culture replicates from one donor, not four donors.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MUC5AC in pooled apical washes at 24 hrIC50 (95% CI) 96 (85–109) μM[1]
Cellular MUC5AC content at 24 hrIC50 (95% CI) 150 (95–330) μM[1]
Cell viability at 3, 8 and 24 hrStatistical comparison No significant change versus IL-13-only control[1]

Literature-Reported Treatment Conditions

Treatment concentration
10, 30, 100 and 300 μM guaifenesin; IL-13 1 ng/mL
Exposure duration
3, 8 or 24 hr after 3 days of IL-13 pre-treatment; IC50 estimates selected only at 24 hr.
Method
Basolateral addition; IL-13 continued. Apical surfaces washed immediately before drug exposure. Controls: IL-13 alone and neither IL-13 nor drug.
Vehicle
Culture medium
Co-treatment
IL-13 stimulation; NAC and ambroxol were separate comparator treatments, not co-administered with guaifenesin.
Reported limits
Reagent purity and stereochemical composition not specified in read methods. No donor replication.
Methods and source locations

Compound reported in the paper: Guaifenesin; Compound label in the paper: GGE

Evidence concerns the reported guaifenesin reagent, not an Adooq lot or a clinical formulation.

Materials and methods: Cell cultures and exposures; Cell viability and cellular levels and release of MUC5AC; MUC5AC ELISA; Statistical analysis; Results: Viability and MUC5AC secretion and content; Figures 3–5

MUC5AC in pooled apical washes at 24 hr: MUC5AC ELISA; exponential-decay fit — Results: MUC5AC secretion and content; Figure 4, 24 hr; Statistical analysis

Cellular MUC5AC content at 24 hr: MUC5AC ELISA in lysates; exponential-decay fit — Results: MUC5AC secretion and content; Figure 5, 24 hr

Cell viability at 3, 8 and 24 hr: WST-1; ANOVA with Dunnett’s post-test — Results: Viability; Figure 3

Linked mucus transport and rheology in IL-13-stimulated airway cultures

Cell-based study · Primary human tracheal-bronchial epithelial cultures (MatTek EpiAirway), differentiated at air–liquid interface; a single donor. [1]

The linked design measured endogenous particle/mucus-sheet motion and then collected secretions for rheology. Guaifenesin had no significant transport effect at 3 hr; later effects depended on concentration, time and particle class. Lower mucus moduli accompanied later transport improvement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Transport of endogenous material at 3 hrStatistical comparison No significant guaifenesin effect versus IL-13 alone[1]
Transport rate for combined particles and mucus sheets at 24 hrFold change versus IL-13 alone 30 μM: over 6-fold; 100 μM: 3-fold[1]
Elastic (G′) and viscous (G″) moduli of apical secretions at 24 hrApproximate reduction versus IL-13 alone Approximately one order of magnitude at 30 and 100 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
30 or 100 μM guaifenesin; IL-13 1 ng/mL
Exposure duration
Transport assessed at 3, 8 and 24 hr after 3 days of IL-13 pre-treatment; selected rheology outcome at 24 hr.
Method
Basolateral treatment. Cultures washed 24 hr before drug exposure. Initial sextuplicate cultures; secretions harvested from two after 8 hr and four after 24 hr. Imaging targeted three fields and at least five moving elements per field in four cultures, not always attained.
Vehicle
Culture medium
Co-treatment
IL-13 stimulation; comparator drugs tested separately.
Reported limits
Single donor; no fixed achieved particle count per condition. Eight-hour rheology was incomplete because material was insufficient.
Methods and source locations

Compound reported in the paper: Guaifenesin; Compound label in the paper: GGE

Evidence concerns the reported guaifenesin reagent, not an Adooq lot or a clinical formulation.

Materials and methods: Cell cultures and exposures; Mucociliary transport; Rheology; Results: Mucociliary transport and Rheology; Figures 6–7; Discussion limitations

Transport of endogenous material at 3 hr: Videomicroscopy of moving endogenous particles and mucus sheets — Results: Mucociliary transport; Figure 6, 3 hr

Transport rate for combined particles and mucus sheets at 24 hr: Reported text estimates; both significant for combined material. Not read as exact rates from figure. — Results: Mucociliary transport; Figure 6, 24 hr all

Elastic (G′) and viscous (G″) moduli of apical secretions at 24 hr: Parallel-plate rheometry, 1 Hz, 23°C; Figure 7 reports means and SEM — Results: Rheology; Figure 7

Specifications

Manufacturer Adooq Bioscience
CAS Number 93-14-1
Formula C10H14O4
Molecular Weight 198.22
Synonyms Guaiphenesin; Glyceryl guaiacolate
SMILES
COC1=CC=CC=C1OCC(CO)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 36 mg/mL (181.61 mM)
Water 23 mg/mL (116.03 mM)
Ethanol 36 mg/mL (181.61 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Guaifenesin (Guaiphenesin) Research References

  1. [1] JeanClare Seagrave, Helmut H Albrecht, David B Hill, et al. Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells Respiratory Research (2012). PMID: 23113953 DOI: 10.1186/1465-9921-13-98 Source material

Added to your cart

View Cart Checkout
Loading...